The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Systematic comparative analysis of efficacy of EGFR tyrosine kinase inhibitors (TKIs) in the frontline versus salvage therapy of NSCLC.
T. K. Owonikoko
No relevant relationships to disclose
M. Behera
No relevant relationships to disclose
H. N. Tran
No relevant relationships to disclose
Z. Chen
No relevant relationships to disclose
R. P. Chowdry
No relevant relationships to disclose
N. F. Saba
No relevant relationships to disclose
S. S. Ramalingam
No relevant relationships to disclose
F. R. Khuri
No relevant relationships to disclose